LiquidCell Dx publishes Nature research on liquid biopsy forecasting cancer therapy response
Updated
Updated · The National Law Review · May 6
LiquidCell Dx publishes Nature research on liquid biopsy forecasting cancer therapy response
7 articles · Updated · The National Law Review · May 6
The study, led with Stanford and Mayo Clinic, analysed 10 million transcriptomes from 132 tumours and linked pretreatment plasma signals to immunotherapy outcomes in nearly 100 melanoma patients.
It identified nine tumour microenvironment spatial ecotypes detectable from cell-free DNA, suggesting blood tests could replace tumour biopsies and outperform TMB or PD-L1 in survival associations.
LiquidCell Dx said its LiquidTME assay has since shown blinded validation in 34 metastatic melanoma patients at AACR and is being developed across solid tumours and multiple treatment modalities.
Could a new AI blood test make painful tumor biopsies a thing of the past?
This test found nine universal cancer 'ecosystems.' Does this reveal a common weakness for all tumors?
Decoding Tumor Microenvironment Spatial Ecotypes via cfDNA Methylation: LiquidTME’s Breakthrough in Noninvasive Cancer Diagnostics
Overview
In April-May 2026, Stanford and Mayo Clinic researchers, together with LiquidCell Dx, announced the LiquidTME blood test, a breakthrough that uses cfDNA methylation patterns and AI to noninvasively map nine distinct tumor spatial ecotypes from blood. These ecotypes reveal the tumor microenvironment's complex biology and strongly predict immunotherapy response, outperforming current biomarkers like tumor mutational burden. Validated in metastatic melanoma and other cancers, LiquidTME offers broad clinical utility across 17+ tumor types. By reducing ineffective treatments and invasive biopsies, it promises improved patient outcomes and lower healthcare costs. LiquidCell Dx is now commercializing the test while expanding validation and exploring future applications beyond cancer.